2009
DOI: 10.1016/j.vaccine.2008.11.106
|View full text |Cite
|
Sign up to set email alerts
|

Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
35
0

Year Published

2009
2009
2021
2021

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 39 publications
(36 citation statements)
references
References 44 publications
1
35
0
Order By: Relevance
“…After administration of the viral infective dose to monkeys, a consistent viremia was detected, indicating a successful infection. The day of mean viremia was similar to that previously reported by our group in different green monkey assays (19,20,28). The humoral immune response measured by ELISA reached maximal values at day 30 after infection, whereas titers of neutralizing antibodies had maximal values between days 60 and 90 postinfection.…”
Section: Discussionsupporting
confidence: 86%
See 1 more Smart Citation
“…After administration of the viral infective dose to monkeys, a consistent viremia was detected, indicating a successful infection. The day of mean viremia was similar to that previously reported by our group in different green monkey assays (19,20,28). The humoral immune response measured by ELISA reached maximal values at day 30 after infection, whereas titers of neutralizing antibodies had maximal values between days 60 and 90 postinfection.…”
Section: Discussionsupporting
confidence: 86%
“…The anti-DEN IgG antibodies stimulated by immunization were monitored by an amplified sandwich ELISA system as previously described (28). The absorbance at 492 nm was read in a microplate reader (SensIdent Scan; Merck, Germany).…”
Section: Methodsmentioning
confidence: 99%
“…Tetravalent candidate evaluated in mice; monovalent DV1 and DV2 candidates evaluated in NHPs Hermida et al, 2006;Lazo et al, 2014;Valdés et al, 2009a] EDIII-capsid fusion protein (DIIIC) expressed in E. coli Monovalent DV2 candidate evaluated in NHPs [Gil et al, 2015;Suzarte et al, 2014;Valdés et al, 2009b;Zuest et al, 2015] Tetravalent EDIII-STF2 fusion proteins expressed in E. coli Tetravalent candidate evaluated in mice and NHPs [Liu et al, 2015] EDIII-HBcAg fusion protein expressed in P. pastoris Monovalent DV2 candidate evaluated in mice Recombinant EDII-EDIII-NS1 fusion protein expressed in Drosophila S2 Tetravalent lipidated consensus EDIII (LcED III) expressed in E. coli Tetravalent candidate evaluated in mice [Chen et al, 2013;Chiang et al, 2011;Leng et al, 2009] Lipidated EDIII (LED III) expressed in E. coli Monovalent candidates (DV1,2,4) evaluated in mice [Chiang et al, 2011[Chiang et al, , 2013a MixBiEDIII: bivalent EDIIIs (DV1-2/ DV3-4) expressed in E. coli Tetravalent candidate evaluated in mice [Zhao et al, 2014] Bivalent EDIII (DV1-2) expressed in E. coli Bivalent candidate (DV1-2) evaluated in mice [Zhang et al, 2015] Tetravalent chimeric EDIII expressed in P. pastoris Tetravalent candidate evaluated in mice [Etemad et al, 2008] Non-structural proteins Recombinant DV2 NS1 protein expressed in E. coli Monovalent DV2 candidate evaluated in mice [Amorim et al, 2012] Recombinant DV2 NS1-DEC205 fusion protein expressed in E. coli Monovalent DV2 candidate evaluated in mice [Henriques et al, 2013] Full-length recombinant DV2 NS3 protein expressed in E. coli Monovalent DV2 candidate evaluated in mice [Ramírez et al, 2014] Capsid protein Recombinant capsid protein expressed in E. coli Monovalent DV2 candidate evaluated in mice and NHPs …”
Section: Ediii-p64k Fusion Proteins Expressed In Escherichia Colimentioning
confidence: 99%
“…Most recently, scientists have been developing candidates targeting Domain III of the DENV E protein (EDIII), exploring use of various DENV antigen/adjuvant combinations, antigen expression and vector delivery systems and assessing the immunogenicity of heterologous prime/ boost vaccination strategies. [106][107][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123] DENVs naturally infect non-human primates (NHPs) and support a sylvatic transmission cycle. 124 All DENV types can infect and replicate in NHPs without adaptation, producing 3 to 7 days of viremia and a robust neutralizing antibody response.…”
Section: Dengue Vaccine Development Overviewmentioning
confidence: 99%
“…NHP studies of monovalent preparations have demonstrated moderate immunogenicity and protection from wild-type DENV challenge. 112,122,144 NHPs immunized with monovalent DENV-1 or DENV-2 candidates using an emulsified Freund's adjuvant developed NAb and were protected against homologous challenge.…”
Section: Candidates In Clinical Developmentmentioning
confidence: 99%